Relationship between genomic variation and response to therapeutic drugs
Research Questions
Which genomic variants lead to differences in how a patient responds to medication, including gene therapy vectors?
How do genomic variants differ among human populations?
Recent News
DGM presents data on genomic variants with potential to affect AAV-mediated gene therapy at the 26th Annual Meeting of the American Society for Gene and Cell Therapy, Los Angeles, CA, May 6th to May 11th, 2023
Rostami, M. R., Leopold, P. L., Vasquez, J. M., de Mulder Rougvie, M., Al Shakaki, A., Hssain, A. A., Robay, A., Hackett, N. R., Mezey, J. G., & Crystal, R. G. (2023). Predicted deleterious variants in the human genome relevant to gene therapy with adeno-associated virus vectors. Molecular Therapy - Methods & Clinical Development, 31, 101136. doi: 10.1016/j.omtm.2023.101136.
Rodriguez-Flores, J. L., Messai-Badji, R., Robay, A., Temanni, R., Syed, N., Markovic, M., Al-khayat, E., Qafoud, F., Nawaz, Z., Badii, R., Al-Sarraj, Y., Mbarek, H., Al-Muftah, W., Alvi, M., Rostami, M. R., Cruzado, J. C. M., Mezey, J. G., Shakaki, A. A., Malek, J. A., . . . Crystal, R. G. (2022). The QChip1 knowledgebase and microarray for precision medicine in Qatar. npj Genomic Medicine, 7(1), 3. doi: 10.1038/s41525-021-00270-0.